Shots:

• Celleron will receive an exclusive global right for the clinical development- manufacturing- and commercialization of emactuzumab (formerly RG7155 and RO5509554). The companies expect the closing of an agreement by the end of 2020
• 86% of TGCT patients treated with emactuzumab responded to the drug- with 68% of people experiencing a PR within 6 weeks of starting the treatment. The license agreement demonstrated Celleron’s dedication to the development of cancer medicine and its transformational potential for patients inflicted with cancer
• Emactuzumab (RG7155) is an IgG1 mAb- designed to target and deplete macrophages in the tumor tissue.  The therapy targets TAMs by binding to CSF-1R on the cell surface and blocking its activation by CSF-1

­ Ref: Celleron Therapeutics | Image: Roche